Form 8-K - Current report:
SEC Accession No. 0000950170-25-040241
Filing Date
2025-03-17
Accepted
2025-03-17 16:08:34
Documents
12
Period of Report
2025-03-17
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sana-20250317.htm   iXBRL 8-K 52448
2 EX-99.1 sana-ex99_1.htm EX-99.1 440118
  Complete submission text file 0000950170-25-040241.txt   645756

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sana-20250317.xsd EX-101.SCH 31887
14 EXTRACTED XBRL INSTANCE DOCUMENT sana-20250317_htm.xml XML 4892
Mailing Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102
Business Address 188 EAST BLAINE STREET, SUITE 400 SEATTLE WA 98102 (206) 701-7914
Sana Biotechnology, Inc. (Filer) CIK: 0001770121 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39941 | Film No.: 25744468
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)